Details of the Drug
General Information of Drug (ID: DMPKI0N)
| Drug Name | 
                     EBIO 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        10045-45-1; 1-Ethyl-2-benzimidazolinone; 1-EBIO; 1-ethyl-1H-benzo[d]imidazol-2(3H)-one; 1-Ethylbenzimidazolinone; 1-Ethylbenzimidazolin-2-one; 1-ethyl-1,3-dihydro-2h-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-ethyl-1,3-dihydro-; 1-Ethyl-Benzimidazolinone; UNII-M82W79SS4W; 3-ethyl-1H-benzimidazol-2-one; EINECS 233-148-1; CHEMBL452887; M82W79SS4W; CHEBI:34076; CXUCKELNYMZTRT-UHFFFAOYSA-N; 1-ethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one; 1-EB10; EBIO; 1-ethyl-1,3-dihydrobenzimidazol-2-one; Tocris-1041; AC1Q2ZX3; AC1Q2ZX4
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 162.19 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References



